Stockreport

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics, Inc.  (NMRA) 
PDF Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 O [Read more]